deafness

News

FDA clears first genetic hearing loss gene therapy

Regeneron's Otarmeni is the first gene therapy for congenital hearing loss to be cleared by the FDA, and will be made available for free in the US.

News

Black and white image of the side of a baby's face, focused on its ear

Lilly allies with gene-editing firm Seamless on hearing loss

Gene-editing firm Seamless Therapeutics has attracted its first major pharma partner, Eli Lilly, with a $1.12bn alliance focused on hearing loss.

News

Black and white image of a child holding a conch to their ear

Evidence builds behind Regeneron's deafness gene therapy

Ten out of 11 children with congenital deafness treated with a gene therapy developed by Regeneron have seen "notable" improvements in hearing.

News

Sensorion encouraged by deafness gene therapy data

Sensorion's gene therapy for otoferlin-related hearing loss has shown early signs of improving hearing in two toddlers in a phase 1/2 trial.

News

Lilly trumpets early success with deafness gene therapy

Eli Lilly’s acquisition of gene therapy specialist Akouos seems to have paid off, after the lead candidate in the deal restored hearing in a child with congenital deafness

FDA clears first genetic hearing loss gene therapy

Lilly allies with gene-editing firm Seamless on hearing loss

Evidence builds behind Regeneron's deafness gene therapy

Sensorion encouraged by deafness gene therapy data

Lilly trumpets early success with deafness gene therapy

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

deafness

Editor's Picks